This is an HTML version of an attachment to the Official Information request 'Information regarding Dexcom CGMS and Libre FGMS'.

3 December 2020
D Smith
Via Email: [FYI request #14127 email]
Dear D Smith
REQUEST  FOR  INFORMATION:  FREESTYLE  LIBRE  FLASH  GLUCOSE  MONITORING 
SYSTEM,  DEXCOM  CONTINUOUS  GLUCOSE  MONITOR  (CGM),  TANDEM  T:SLIM  X2 
INSULIN PUMP

Thank you for your request dated 14 November 2020 under the Official Information Act 1982 
(OIA) for information relating to blood glucose monitors and insulin pumps. You wrote:
Under  the  Official  Information Act please provide  all  documentation  you  hold  regarding the 
applications,  meetings,  advice,  correspondence  and  decisions  made  regarding  funding  the 
Freestyle Libre Flash Glucose Monitoring System. If possible include the current rank on your 
prioritisation list.

Please also provide all documentation you hold regarding the applications, meetings, advice, 
correspondence and decisions made regarding funding any iteration of the Dexcom Continous 
Glucose Monitor. If possible include the current rank on your prioritisation list. 

Finally please also provide all documentation you hold regarding the Tandem T:slim X2 Insulin 
Pump,  specifically  software  upgrades  to  Basal-IQ  and  Control-IQ  which  allow  the  pump  to 
integrate with the Dexcom G6 CGMS and automatically adjust insulin delivery.

We are able to provide some of the information you have requested however, as your request 
is for a large amount of information which will require extensive research and collation, please 
note that we are unable to provide all of the information requested at this time. We will continue 
to work to collate the information requested and will provide this to you, via email, as soon as 
possible and without undue delay. If you would like to refine the scope of your request, this 
may assist us with collating and preparing information for release more quickly.
In the meantime, please find some information relevant to your request below.
PHARMAC currently has two (2) active funding applications for blood glucose monitors:
1. Medtronic continuous glucose monitoring systems - Guardian 3 and Guardian Connect; 
and
2. FreeStyle Libre flash glucose monitoring system.
PHARMAC has not yet made a decision for either of these funding applications. 
Please refer to the PHARMAC Application Tracker to view the status and public information 
for these applications, including links to related clinical advice meeting records. The Application 
A1444972; 2020-21-068


Tracker  can be  found on  our  website:  www.pharmac.govt.nz >  top  right  corner: Application 
Tracker.
Additionally, please refer to our OIA response issued 18 November 2020 for information related 
to  the  FreeStyle  Libre  flash  glucose  monitoring  system application.  PHARMAC’s  published 
OIA responses can be found on our website: www.pharmac.govt.nz > About > What we do > 
Accountability information > Official Information Act.
Please note that PHARMAC approaches its assessment of requests for information under the 
OIA on  the  basis  that, once  released,  the  information becomes publicly available  - in other 
words once we release the information to you it becomes available to any other party in that 
exact form (whether by you distributing it to others or by virtue of us receiving the same request 
from a different third party).  
We  are  unable  to provide  the  specific  rank of  the  FreeStyle Libre  flash glucose monitoring 
system application on our Options for Investment (prioritisation) list as we believe this would 
impact  on  PHARMAC’s  ability  to  carry  on,  without  prejudice  or  disadvantage,  negotiations, 
including  commercial  negotiations (section  9(2)(j)) of  the  OIA).  Additionally,  as  no  current 
funding application exists for any iteration of the Dexcom continuous glucose monitor (CGM), 
we are unable to provide any rank information for this pharmaceutical as the information is not 
held by PHARMAC and we have no grounds to believe the information is held by any other 
agency (section 18(g) of the OIA).
As required under the OIA, we also considered whether, in the circumstances, the withholding 
of this information was outweighed by other considerations which render it desirable, in the 
public interest, to make this information available.  In this case we did not consider that the 
public interest outweighed the reasons for withholding the information.
Please  note  you  have  the  right,  by  way  of  complaint  under  section  28(3)  of  the  OIA  to  an 
Ombudsman, to seek an investigation and review of our decision.
We  will  continue  to  collate  information  considered  in  scope  of  your  request,  received  14 
November  2020,  relating  to  the  FreeStyle  Libre  flash  glucose  monitoring  system,  Dexcom 
continuous glucose monitor and the Tandem T:slim X2 insulin pump and aim to provide this 
information in January 2021. 
We  are making  our  information  more  freely  available,  so  we  will  now publish  selected  OIA 
responses (excluding personal details) on our website. Please get in touch with us if you have 
any questions about this.
Yours sincerely
Rachel Read
Manager, Policy and Government Services
A1444972; 2020-21-068
qA57457
2

Document Outline